AR044732A1 - Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica - Google Patents

Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica

Info

Publication number
AR044732A1
AR044732A1 ARP020104293A ARP020104293A AR044732A1 AR 044732 A1 AR044732 A1 AR 044732A1 AR P020104293 A ARP020104293 A AR P020104293A AR P020104293 A ARP020104293 A AR P020104293A AR 044732 A1 AR044732 A1 AR 044732A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
appropriate
benigan
prostata
hyperplasia
Prior art date
Application number
ARP020104293A
Other languages
English (en)
Inventor
Hipolito Carmelo Maria Barreiro
Original Assignee
H P B S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H P B S A filed Critical H P B S A
Priority to ARP020104293A priority Critical patent/AR044732A1/es
Priority to ES03024296T priority patent/ES2272875T3/es
Priority to EP03024296A priority patent/EP1417969B1/en
Priority to AT03024296T priority patent/ATE338560T1/de
Priority to US10/697,264 priority patent/US20040131694A1/en
Publication of AR044732A1 publication Critical patent/AR044732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición farmacéutica que cada 1 ml contiene: Polisacáridos de Gérmenes Gram Negativos: entre 0,05 gr. y 0,002 gr.; Timo (extracto hidrosoluble): entre 2 mg. y 0,1 mg.; Próstata (extracto hidrosoluble): entre 1 mg. y 0,01 mg.; Carbohidrato totales (glucosa): entre 2 mg. y 0,02 mg.; Solución Fisiológica estéril: c.s.p 1 ml.; método de preparación de la composición indicada, que comprende un método apropiado para cultivar bacterias del género Pseudomona en las siguientes condiciones: a) el cultivo del referido polisacárido se realiza en un medio líquido del mismo modo especializado como se lo hace habitualmente, recordando siempre que se debe trabajar en condiciones rigurosas de asepsia bacteriológica; b) se debe disponer de una cepa apropiada, la cual deberá ser tipificada previamente mediante las pruebas bioquímicas correspondientes: La aplicación de la composición indicada, en dosis adecuadas, para el tratamiento de la Hiperplásica Benigna de la Próstata.
ARP020104293A 2002-11-02 2002-11-08 Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica AR044732A1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ARP020104293A AR044732A1 (es) 2002-11-08 2002-11-08 Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
ES03024296T ES2272875T3 (es) 2002-11-08 2003-10-23 Una composicion farmaceutica para el tratamiento medico de la hiperplasia benigna de la prostata, su metodo de preparacion y su aplicacion terapeutica.
EP03024296A EP1417969B1 (en) 2002-11-08 2003-10-23 A pharmaceutical composition for the medical treatment of the benign prostatic hyperplasia, its preparation method and its therapeutical application
AT03024296T ATE338560T1 (de) 2002-11-08 2003-10-23 Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
US10/697,264 US20040131694A1 (en) 2002-11-02 2003-10-31 Pharmaceutical composition for the medical treatment of the benign prostatic hyperplasia, its preparation method and its therapeutic application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP020104293A AR044732A1 (es) 2002-11-08 2002-11-08 Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica

Publications (1)

Publication Number Publication Date
AR044732A1 true AR044732A1 (es) 2005-10-05

Family

ID=32097251

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104293A AR044732A1 (es) 2002-11-02 2002-11-08 Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica

Country Status (5)

Country Link
US (1) US20040131694A1 (es)
EP (1) EP1417969B1 (es)
AR (1) AR044732A1 (es)
AT (1) ATE338560T1 (es)
ES (1) ES2272875T3 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR055311A1 (es) * 2006-02-17 2007-08-15 H P B S A Composicion farmaceutica solida para el tratamiento de la hiperplasia benigna de prostata, procedimiento para su elaboracion y metodo de tratamiento

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295961A3 (en) * 1987-06-18 1989-07-12 Kureha Kagaku Kogyo Kabushiki Kaisha Polysaccharides and antiviral drug containing polysaccharides as active ingredient
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5972615A (en) * 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
NZ509976A (en) * 1998-08-03 2003-08-29 Ronald E Prostate formula
US6200573B1 (en) * 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
IT1320180B1 (it) * 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
ES2409782T3 (es) * 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents

Also Published As

Publication number Publication date
EP1417969A1 (en) 2004-05-12
ES2272875T3 (es) 2007-05-01
US20040131694A1 (en) 2004-07-08
ATE338560T1 (de) 2006-09-15
EP1417969B1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
Rowen et al. A plausible “penny” costing effective treatment for corona virus-ozone therapy
Hönigsmann History of phototherapy in dermatology
Wainwright Photodynamic antimicrobial chemotherapy (PACT).
ATE281839T1 (de) Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut
Hu et al. Preparation and in vivo. Antitumor activity of κ-carrageenan oligosaccharides
WO2007023398A3 (en) Compounds for photochemotherapy
AR042795A1 (es) Fluidos de dialisis biocompatibles que contienen icodextrinas
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
Braun-Falco et al. Leucine aminopeptidase activity in mast cells
Mori et al. Photodynamic therapy for experimental tumors using ATX‐S10 (Na), a hydrophilic chlorin photosensitizer, and diode laser
Jakopovich New dietary supplements from medicinal mushrooms: Dr Myko San—a registration report
CN115212243B (zh) 淫羊藿提取物的应用
Vogel et al. γ-L-Glutaminyl-4-hydroxybenzene, an inducer of cryptobiosis in Agaricus bisporus and a source of specific metabolic inhibitors for melanogenic cells
AR044732A1 (es) Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica
Ma et al. Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment
Jagetia et al. Treatment with Alstonia scholaris enhances radiosensitivity in vitro and in vivo
CN107412312A (zh) 一种治疗勃起功能障碍的男性保健组合物
CN100348209C (zh) 天然番茄红素复合油制剂和胶囊及其制备方法和用途
González et al. Rethinking vitamin C and cancer: an update on nutritional oncology
Khalikova et al. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide
CN102363044B (zh) 靶向线粒体的三种蒽醌类物质作为鼻咽癌放射增敏剂的用途
Pannu et al. The green blood” wheatgrass juice, a health tonic having antibacterial potential
Ojewole P-2: Hypotensive effect of Leonotis leonurus aqueous leaf extract in rats
Zanin et al. In-vitro study of bactericidal effect of low-level laser therapy in the presence of photosensitizer on cariogenic bacteria
Kolesnik et al. Lewis lung carcinoma variant with a high sensitivity to antitumor antiangiogenic therapy exhibits a high capacity for autophagy

Legal Events

Date Code Title Description
FB Suspension of granting procedure